Short answer
Oncology Institute, Inc. (TOI) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $147M (up 41.2% year over year) with net income of −$2M.
Q1 2026 key financials · XBRL
- Revenue
- $147M
- +41.2% YoY
- Net income
- −$2M
- +87.3% YoY
- Operating margin
- -4.4%
- EPS (diluted)
- −$0.02
- +90.5% YoY
Source: XBRL data from the Oncology Institute, Inc. (TOI) Q1 2026 10-Q on SEC EDGAR. USD.
Oncology Institute, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $147.441M, up 41.2% YoY from $104.406M
- Specialty Pharmacy best performer: $87.541M, up 77.6% YoY; Clinical trials & other worst: $813K, down 60.2%
- Operating margin (4.4%) vs (9.5%) YoY; net loss margin (1.7%) vs (18.7%)
- Cash $30.280M; operating cash outflow $2.215M vs $4.988M; investing outflow $1.042M
- Management expects liquidity sufficient for at least one year; AI pilots and next-generation call center planned during the year
Risk Factors
- No risk-factors section provided; supplied text begins with Item 2 rather than risk disclosures
- Insider trading activity: director adopted a Rule 10b5-1 plan covering up to 105,719 shares through October 1, 2026
- Financing exposure: at-the-market sales agreements with BTIG and B. Riley dated August 13, 2025
- Securities compliance: Rule 10b5-1 plan entered during an open trading window to satisfy Rule 10b5-1(c) affirmative defense
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oncology Institute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.